Monte Rosa Therapeutics, Inc.

SEC 4 · Filed

0000899243-21-025978Accepted

Applies to the EDGAR acceptance time.

Other time zone
Insider transactionsEvent date Jun 23, 2021

Grant, award or other acquisition by Bolzon Bradley J PhD

Security
Stock Option (Right to Buy)
Code
A
Shares
47,132
Price per share
0.00
Structured facts
{
  "code": "A",
  "date": "2021-06-23",
  "direction": "A",
  "exercise_price": "19.00",
  "expiration": "2031-06-22",
  "footnotes": {
    "F5": "This option shall vest in 36 substantially equal monthly installments, with the first installment vesting on June 28, 2021."
  },
  "owners": [
    {
      "cik": "0001354345",
      "name": "Bolzon Bradley J PhD",
      "roles": [
        "director",
        "ten_percent_owner"
      ],
      "title": null
    }
  ],
  "ownership": "D",
  "post_shares": "47132",
  "price": "0.00",
  "row": 4,
  "rule_10b5_1": null,
  "security": "Stock Option (Right to Buy)",
  "shares": "47132",
  "table": "II",
  "underlying_security": "Common Stock",
  "underlying_shares": "47132"
}
Insider transactionsEvent date Mar 11, 2021

Grant, award or other acquisition by Bolzon Bradley J PhD

Security
Series C convertible preferred stock
Code
A
Shares
2,699,328
Price per share
2.96Reported 2.9637
Structured facts
{
  "code": "A",
  "date": "2021-03-11",
  "direction": "A",
  "exercise_price": null,
  "expiration": null,
  "footnotes": {
    "F1": "Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") is convertible into shares of the Issuer\u0027s Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer\u0027s initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date.",
    "F2": "This transaction occurred prior to the Issuer\u0027s initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The securities covered by such transaction were previously included on the Reporting Person\u0027s Form 3.",
    "F4": "Shares held by Versant Vantage I, L.P. (\"Versant Vantage I\"). Versant Vantage I GP, (\"Versant Vantage I GP\") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC (\"Versant Vantage I GP-GP\") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."
  },
  "owners": [
    {
      "cik": "0001354345",
      "name": "Bolzon Bradley J PhD",
      "roles": [
        "director",
        "ten_percent_owner"
      ],
      "title": null
    }
  ],
  "ownership": "I",
  "post_shares": "2699328",
  "price": "2.9637",
  "row": 3,
  "rule_10b5_1": null,
  "security": "Series C convertible preferred stock",
  "shares": "2699328",
  "table": "II",
  "underlying_security": "Common Stock",
  "underlying_shares": "764573"
}
Insider transactionsEvent date Feb 24, 2021

Grant, award or other acquisition by Bolzon Bradley J PhD

Security
Series B convertible preferred stock
Code
A
Shares
2,075,000
Price per share
2.00
Structured facts
{
  "code": "A",
  "date": "2021-02-24",
  "direction": "A",
  "exercise_price": null,
  "expiration": null,
  "footnotes": {
    "F1": "Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") is convertible into shares of the Issuer\u0027s Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer\u0027s initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date.",
    "F2": "This transaction occurred prior to the Issuer\u0027s initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The securities covered by such transaction were previously included on the Reporting Person\u0027s Form 3.",
    "F4": "Shares held by Versant Vantage I, L.P. (\"Versant Vantage I\"). Versant Vantage I GP, (\"Versant Vantage I GP\") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC (\"Versant Vantage I GP-GP\") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."
  },
  "owners": [
    {
      "cik": "0001354345",
      "name": "Bolzon Bradley J PhD",
      "roles": [
        "director",
        "ten_percent_owner"
      ],
      "title": null
    }
  ],
  "ownership": "I",
  "post_shares": "4150000",
  "price": "2.00",
  "row": 2,
  "rule_10b5_1": null,
  "security": "Series B convertible preferred stock",
  "shares": "2075000",
  "table": "II",
  "underlying_security": "Common Stock",
  "underlying_shares": "587735"
}
Insider transactionsEvent date Feb 24, 2021

Grant, award or other acquisition by Bolzon Bradley J PhD

Security
Series B convertible preferred stock
Code
A
Shares
1,500,000
Price per share
2.00
Structured facts
{
  "code": "A",
  "date": "2021-02-24",
  "direction": "A",
  "exercise_price": null,
  "expiration": null,
  "footnotes": {
    "F1": "Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") is convertible into shares of the Issuer\u0027s Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer\u0027s initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date.",
    "F2": "This transaction occurred prior to the Issuer\u0027s initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). The securities covered by such transaction were previously included on the Reporting Person\u0027s Form 3.",
    "F3": "Shares held by Versant Venture Capital VI, L.P. (\"Versant VI\"). Versant Ventures VI GP, L.P. (\"Versant Ventures VI GP\") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC (\"Versant Ventures VI GP-GP\") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any."
  },
  "owners": [
    {
      "cik": "0001354345",
      "name": "Bolzon Bradley J PhD",
      "roles": [
        "director",
        "ten_percent_owner"
      ],
      "title": null
    }
  ],
  "ownership": "I",
  "post_shares": "3000000",
  "price": "2.00",
  "row": 1,
  "rule_10b5_1": null,
  "security": "Series B convertible preferred stock",
  "shares": "1500000",
  "table": "II",
  "underlying_security": "Common Stock",
  "underlying_shares": "424869"
}